share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  07/19 18:36
牛牛AI助理已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise listed on both ASX (ATH) and NASDAQ (ATHE), has filed a Form 6-K with the Securities and Exchange Commission for the month of July 2024. The report, which serves as a notification of foreign private issuer, indicates that Alterity Therapeutics has complied with the necessary provisions of the Corporations Act 2001 (Cth) as they apply to the company. On July 18, 2024, Alterity issued 75,220,800 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has confirmed that as of the date of the notice, it has adhered to the requirements of Chapter 2M of the Corporations Act, as well as sections 674 and 674A. Furthermore, there is no 'excluded information' as defined in sections 708A(7) and 708A(8) of the Corporations Act that needs to be disclosed. This Form 6-K is also incorporated by reference into Alterity's Registration Statements on Form S-8 and Form F-3.
Alterity Therapeutics Limited, a development stage enterprise listed on both ASX (ATH) and NASDAQ (ATHE), has filed a Form 6-K with the Securities and Exchange Commission for the month of July 2024. The report, which serves as a notification of foreign private issuer, indicates that Alterity Therapeutics has complied with the necessary provisions of the Corporations Act 2001 (Cth) as they apply to the company. On July 18, 2024, Alterity issued 75,220,800 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has confirmed that as of the date of the notice, it has adhered to the requirements of Chapter 2M of the Corporations Act, as well as sections 674 and 674A. Furthermore, there is no 'excluded information' as defined in sections 708A(7) and 708A(8) of the Corporations Act that needs to be disclosed. This Form 6-K is also incorporated by reference into Alterity's Registration Statements on Form S-8 and Form F-3.
Alterity therapeutics有限公司是一家發展階段的企業，在ASX（ATH）和納斯達克（ATHE）上市，並已向證券交易委員會提交了2024年7月的6-K格式申報。該報告作爲外國私人發行人的通知，表明Alterity therapeutics已經遵守了適用於該公司的2001年《公司法》，聲明Alterity therapeutics於2024年7月18日發佈了75220800個完全實繳普通股，未按照《公司法》第6D.2部分披露。公司已經確認，截至該通知日期，它已經遵守了《公司法》第200萬章節的要求，以及674和674A條。此外，根據《公司法》第708A（7）條和第708A（8）條的定義，沒有需要披露的“排除信息”。此6-k表格還被納入Alterity's S-8和F-3表格的註冊聲明中。
Alterity therapeutics有限公司是一家發展階段的企業，在ASX（ATH）和納斯達克（ATHE）上市，並已向證券交易委員會提交了2024年7月的6-K格式申報。該報告作爲外國私人發行人的通知，表明Alterity therapeutics已經遵守了適用於該公司的2001年《公司法》，聲明Alterity therapeutics於2024年7月18日發佈了75220800個完全實繳普通股，未按照《公司法》第6D.2部分披露。公司已經確認，截至該通知日期，它已經遵守了《公司法》第200萬章節的要求，以及674和674A條。此外，根據《公司法》第708A（7）條和第708A（8）條的定義，沒有需要披露的“排除信息”。此6-k表格還被納入Alterity's S-8和F-3表格的註冊聲明中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。